Therapy Detail

Therapy Name AT7519
Therapy Description

AT7519 is an ATP competitive inhibitor of CDK1, CDK2, CDK4, CDK5, CDK6, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 19174555).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AT7519 AT7519M CDK1 Inhibitor 12 CDK2 Inhibitor 16 CDK4 Inhibitor 12 CDK4/6 Inhibitor 8 CDK5 Inhibitor 6 CDK6 Inhibitor 3 CDK9 Inhibitor 11 AT7519 is an ATP competitive inhibitor of CDK1, CDK2, CDK4, CDK5, CDK6, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 19174555).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable AT7519 Phase I Actionable In a Phase I trial, AT7519 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 25393368). 25393368
Clinical Trial Phase Therapies Title Recruitment Status
NCT02503709 Phase I AT7519 AT13387 Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting